Peter Langmuir

6.1k total citations · 2 hit papers
56 papers, 4.7k citations indexed

About

Peter Langmuir is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Peter Langmuir has authored 56 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 14 papers in Genetics. Recurrent topics in Peter Langmuir's work include Lung Cancer Treatments and Mutations (20 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Peter Langmuir is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Peter Langmuir collaborates with scholars based in United States, United Kingdom and Italy. Peter Langmuir's co-authors include Jessica Read, Anderson J. Ryan, Laurence A. Turka, Mohamed H. Sayegh, Samuel A. Wells, James R. Vasselli, Éric Baudin, Barbara Jarząb, Martin Schlumberger and Rossella Elisei and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Peter Langmuir

54 papers receiving 4.6k citations

Hit Papers

Vandetanib in Patients With Locally Advanced or Metastati... 2011 2026 2016 2021 2011 2021 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
    2011 1.1k citations Samuel A. Wells, Bruce G. Robinson et al. Journal of Clinical Oncology profile →
  2. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
    2021 271 citations Robert Zeiser, Nicola Polverelli et al. profile →

Peers

Peter Langmuir
Lance C. Pagliaro United States
Jean-Pascal Machiels Belgium
Christiane De Wolf‐Peeters Belgium
Silvana Del Vecchio Italy
Andréa Varga France
Suneel Mundle United States
Paul Hoskins Canada
Ranee Mehra United States
Gerold Meinhardt United States
Allen Lee Cohn United States
Lance C. Pagliaro United States
Peter Langmuir
Citations per year, relative to Peter Langmuir Peter Langmuir (= 1×) peers Lance C. Pagliaro

Countries citing papers authored by Peter Langmuir

Since Specialization
Citations

This map shows the geographic impact of Peter Langmuir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Langmuir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Langmuir more than expected).

Fields of papers citing papers by Peter Langmuir

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Langmuir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Langmuir. The network helps show where Peter Langmuir may publish in the future.

Co-authorship network of co-authors of Peter Langmuir

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Langmuir. A scholar is included among the top collaborators of Peter Langmuir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Langmuir. Peter Langmuir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Talpaz, Moshe, Aaron T. Gerds, Roger M. Lyons, et al.. (2025). A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis. Leukemia Research. 155. 107732–107732.
3.
4.
Hamadani, Mehdi, Morton Coleman, Ralph V. Boccia, et al.. (2023). Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL‐102): A phase 1 study. Hematological Oncology. 41(5). 848–857. 1 indexed citations
5.
Guglielmelli, Paola, et al.. (2022). JAK inhibitors and COVID-19. Journal for ImmunoTherapy of Cancer. 10(4). e002838–e002838. 43 indexed citations
6.
Zeiser, Robert, Nicola Polverelli, Ron Ram, et al.. (2021). Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (Pts) with Glucocorticoid-Refractory Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study. Transplantation and Cellular Therapy. 27(3). S78–S79. 1 indexed citations
7.
Schroeder, Mark A., H. Jean Khoury, Madan Jagasia, et al.. (2020). A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. Blood Advances. 4(8). 1656–1669. 72 indexed citations
8.
Yeleswaram, Swamy, Paul Smith, Timothy C. Burn, et al.. (2020). Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment. Clinical Immunology. 218. 108517–108517. 70 indexed citations
9.
Verstovšek, Srđan, Jason Gotlib, Ruben A. Mesa, et al.. (2017). Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. Journal of Hematology & Oncology. 10(1). 156–156. 193 indexed citations
10.
11.
Wells, Samuel A., Bruce G. Robinson, Robert F. Gagel, et al.. (2011). Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. Journal of Clinical Oncology. 30(2). 134–141. 1082 indexed citations breakdown →
12.
Langmuir, Peter & Antoine Yver. (2011). Vandetanib for the Treatment of Thyroid Cancer. Clinical Pharmacology & Therapeutics. 91(1). 71–80. 36 indexed citations
13.
Martin, Paul, et al.. (2010). Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment. Clinical Pharmacokinetics. 49(9). 607–618. 26 indexed citations
14.
Hanrahan, Emer O., Anderson J. Ryan, Helen Mann, et al.. (2009). Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer. Clinical Cancer Research. 15(10). 3600–3609. 69 indexed citations
15.
Hanrahan, Emer O., Heather Lin, Edward S. Kim, et al.. (2009). Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 28(2). 193–201. 102 indexed citations
16.
Eberhardt, Wilfried, S. Korfee, Bruce E. Johnson, et al.. (2007). PD3-3-4: Vandetanib in advanced NSCLC: an ongoing clinical evaluation program. Journal of Thoracic Oncology. 2(8). S467–S468. 2 indexed citations
17.
Sayegh, Mohamed H., Zihao Wu, Wayne W. Hancock, et al.. (2003). Allograft Rejection in a New Allospecific CD4+ TCR Transgenic Mouse. American Journal of Transplantation. 3(4). 381–389. 47 indexed citations
18.
Kishimoto, Koji, Sigrid Sandner, Jaime Imitola, et al.. (2002). Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. Journal of Clinical Investigation. 109(11). 1471–1479. 57 indexed citations
19.
Kishimoto, Koji, Sigrid Sandner, Jaime Imitola, et al.. (2002). Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. Journal of Clinical Investigation. 109(11). 1471–1479. 4 indexed citations
20.
Langmuir, Peter, et al.. (2001). Quantifying the Frequency of Alloreactive T Cells In Vivo: New Answers to an Old Question. The Journal of Immunology. 166(2). 973–981. 422 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lance C. Pagliaro Breakdown of academic impact, for papers by Jean-Pascal Machiels Breakdown of academic impact, for papers by Christiane De Wolf‐Peeters Breakdown of academic impact, for papers by Silvana Del Vecchio Breakdown of academic impact, for papers by Andréa Varga Breakdown of academic impact, for papers by Suneel Mundle Breakdown of academic impact, for papers by Paul Hoskins Breakdown of academic impact, for papers by Ranee Mehra Breakdown of academic impact, for papers by Gerold Meinhardt Breakdown of academic impact, for papers by Allen Lee Cohn
Rankless by CCL
2026